CENTOGENE Woman looking into distance

Genetic Testing for Hereditary Cancers Can Help Reduce the Risk of Cancer

By detecting cancer early, your patient will have access to preventative measures and proactive treatment – leading to an overall better prognosis.

Order a test  Learn more

Genetic Diagnosis of Hereditary Cancer

Testing for hereditary cancers can detect specific, heritable, disease-related gene mutations that may increase the risk of certain cancers allowing an in-depth cancer risk assessment for each patient.

The critical goal is to detect cancer early and to give you the opportunity to maximize health outcomes for your patients. Patient-tailored screening programs, preventive measures and proactive treatment are possible for patients of a high-risk group. Early diagnosis can mean a better overall prognosis through a choice of surgical and non-surgical treatment options.

Hereditary Cancer Feature List

Excellent analysis using the most advanced NGS technology

Includes detection of Copy Number Variants (CNVs)

Affordable prices and shortest turnaround times

Highest level of quality/accuracy

CAP and CLIA and ISO certification and accreditation

CENTOGENE Two Women on Park Bench

Breast and Ovarian Cancer

Providing critical information for affected and non-affected individuals

Learn more

CENTOGENE Hands of Two Women

Comprehensive Cancer Panel

CentoCancer® – CENTOGENE's cancer-risk-related panel, for all patients with a positive family history of cancer

Learn more

Visit Our Online Ordering Portal

CentoPortal® is a user-friendly, online, web-based ordering portal designed to assist you at every step of processing your patients' samples.

Order a Test

CENTOGENE CentoPortal Logo

Breast and Ovarian Cancer

Breast cancer is one of the most common cancers in the world affecting ~12.5% of women during their lifetime. 5–10% of these patients have a hereditary form.

Mutations in the BRCA1 and BRCA2 genes are the most common hereditary cause. However, other genes such as ATM, BRIP1, CHEK2, PALB2, RAD51, etc. have also been associated with increased risk.

Gene test

BRCA1/BRCA2 

CentoBreast®

Gene name BRCA1, BRCA2 ABRAXAS1, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, FANCC, MEN1, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS1, PMS2, PTEN, RAD50, RAD51C, RAD51D, RECQL, SMARCA4, STK11, TP53, XRCC2
Diseases covered Breast cancer Breast cancer, ovarian cancer
Turnaround time 15 business days 15 business days
How to order Order a test Order a test

Comprehensive Cancer Panel

CentoCancer® is a specific and sensitive panel with all known highly penetrant cancer genes. Each gene has been carefully selected based on its risk potential in the development of one of the following cancers: breast, ovarian, colorectal, gastric, bowel, endometrial, pancreatic, melanoma, renal and prostate cancer.

Gene test

CentoCancer®

Genes name ABRAXAS1, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, DICER1, DIS3L2, EPCAM, FANCC, FH, FLCN, GALNT12, HNF1B, HOXB13, KIT, MC1R, MEN1, MET, MITF, MLH1, MLH3, MRE11, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PMS1, PMS2, POLD1, POLE, POT1, PRSS1, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RECQL, RET, RNF43, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, TGFBR2, TP53, TSC1, TSC2, VHL, WT1, XRCC2, XRCC3
Diseases covered Breast, ovarian, colorectal, gastric, bowel, endometrial, pancreatic, melanoma, renal and prostate cancer
Turnaround time 15 business days
How to order Order a test
Resources

Downloads

Hereditary Cancer Panels – Product Sheet

Genetic testing for an improved prognosis

Scientific Publications

Ultra-Rare Immune Disorder Uncovered

Homeostasis of the immune system is key for human health. Recently, CENTOGENE carried out an analysis of clinical and genetic data from the CENTOGENE Biodatabank, which enabled the identification of […]

Article
25 Aug, 2022
Loading...

Related Webinars

MOx – Advancing Rare Disease Patient Care With Multiomic Solutions

Watch the on-demand webinar now to gain insights into our multiomics revolution – a multidimensional approach looking at each patient from different angles to combine deep knowledge and insights for […]

Loading...

Rewrite the Future of Rare Diseases With Multiomics

Our speakers, Maximilian Schmid M.D., Chief Commercial Officer – Diagnostics, and Prof. Peter Bauer M.D., Chief Genomic Officer, will highlight the power of multiomics in establishing a complete […]

Loading...

NEW CentoXome® – Turning Our Expertise Into Your Advantage

Dr. Aida Bertoli-Avella and Dr. Jorge Pinto-Pasto provide you with an exclusive look into our enhanced Whole Exome Sequencing (WES) solution – NEW CentoXome.

Loading...

Get in Touch With Our Customer Support

Our consultation service is available in several languages.

+49 (0) 381 80 113 - 416

Mon. – Fri. 7 a.m. – 6:30 p.m. CET
Sat. 8 a.m. – 12 p.m. CET

Contact Us

For our US Partners:

+1 (617) 580 - 2102

Mon. – Fri. 9 a.m. – 5:30 p.m. EST


Contact Us